Bluebird Bio
BLUE
shares ended the last trading session 18% higher at $5.05. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock’s 43.6% gain over the past four weeks.
Shares surged as investors are more likely impressed by bluebird’s recent pipeline progress. The company recently received positive recommendation for its gene therapy candidates, for beta thalassemia and cerebral adrenoleukodystrophy (CALD), from FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC). The CTGTAC voted unanimously recommending the benefits of treatment.
This biotechnology company is expected to post quarterly loss of $1.28 per share in its upcoming report, which represents a year-over-year change of +64.3%. Revenues are expected to be $12.43 million, up 66.4% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Bluebird, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
Bluebird belongs to the Zacks Medical – Biomedical and Genetics industry. Another stock from the same industry,
Vanda Pharmaceuticals
VNDA
, closed the last trading session 2.8% higher at $11.50. Over the past month, VNDA has returned 12.2%.
For Vanda
, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.11. This represents a change of -35.3% from what the company reported a year ago. Vanda currently has a Zacks Rank of #3 (Hold).
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
